Latest News and Press Releases

NEEDHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges...

NEEDHAM, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious...

MYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass.,...

NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage...

MYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for...

NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3...